Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ESRRB | O95718 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28628216 | 0.89 | ALDH1A1 (0.49) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL17045863 | 0.82 | CA12 (0.49) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL18922451 | 0.81 | CES2 (0.41) | LMNAALDH1A1 | |
| SCHEMBL11895137 | 0.79 | TSHR (0.58) | LMNAKDM4EALDH1A1CA12CA14 | |
| SCHEMBL10805196 | 0.78 | HDAC3 (0.53) | LMNAALDH1A1LTA4HTSHRLTB4R | |
| SCHEMBL20545009 | 0.78 | LMNA (0.47) | LMNAKDM4EALDH1A1TBXAS1AKT1 | |
| SCHEMBL29131269 | 0.77 | LMNA (0.44) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL117432 | 0.76 | MAPT (0.61) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL20717644 | 0.74 | MAPT (0.65) | CA12CA7CA9CA14 | |
| SCHEMBL9219599 | 0.74 | MAPT (0.65) | CA12CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | claimed |
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | disclosed |
| WO-2020240524-A2 | METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburg—Of the Commonwealth System of Higher Education (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburg—Of the Commonwealth System of Higher Education (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | HDAC1, HDAC9, HDAC11 | LMNA 1928/4885KDM4E 72/4885ALDH1A1 351/4885 |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | MMP8, PLAU, KLKB1 | LMNA 2370/4885KDM4E 4265/4885ALDH1A1 2405/4885 |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | LMNA 1928/4885KDM4E 72/4885ALDH1A1 351/4885 |
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | HDAC1, HDAC2, HDAC4 | LMNA 2466/4885KDM4E 283/4885ALDH1A1 1054/4885 |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | LMNA 1928/4885KDM4E 72/4885ALDH1A1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.